QLC5508 for Advanced Prostate Cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests QLC5508, a new targeted drug for men with metastatic castration-resistant prostate cancer (advanced prostate cancer that has spread and stopped responding to hormone therapy). The drug is designed to work in patients whose cancer has progressed despite prior hormone-based treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a male, age 18 or older
- You have metastatic castration-resistant prostate cancer (mCRPC)—prostate cancer that has spread to other parts of your body and is no longer responding to hormone therapy
- Your cancer has progressed despite prior treatment with newer hormone therapies
- You are in good enough health to tolerate the treatment (ECOG performance status 0 or 1, meaning you can care for yourself with little to no help)
- You have adequate organ function (heart, liver, kidneys, lungs work well enough)
- You have not previously received certain cancer therapies, including B7-H3 targeted therapy or topoisomerase I inhibitor-based drugs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new drug (QLF4113) designed to help the immune system fight metastatic castration-resistant prostate cancer—a type that has spread and stopped responding to standard hormone therapy. You may qualify if you've already tried other treatments and your overall health is stable enough for the study.
This trial tests a new drug, QLG1080, for patients with advanced prostate cancer that still responds to hormone therapy. It aims to see if the drug is safe and effective when combined with standard hormone treatment.
This trial tests two new drugs (QLC5508 and QLH12016) alone or together with other treatments for prostate cancer that has spread to other parts of the body. It may be an option if standard treatments have stopped working or caused side effects.
This trial tests a new drug called QLC5508, given in combination with other treatments, for people with advanced solid tumors that have stopped responding to standard therapy or who haven't had treatment yet. The goal is to see if the combination can shrink tumors or slow their growth.
This trial tests a new combination of drugs (QLC5513 and QL1706) for people with advanced or metastatic solid tumors that cannot be removed by surgery or radiation. The goal is to see if this combination is safe and effective.
This trial tests a new drug, HSK46575, for men with metastatic castration-resistant prostate cancer that has worsened after hormone therapy and chemotherapy. The goal is to see if it can help slow the cancer's growth.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.